SunWay Biotech Co

SunWay Biotech Co Diluted EPS

The Diluted Earnings per Share of SunWay Biotech Co (1271.TWO) as of Oct 20, 2026 is 1.68 TWD. In the previous year, Diluted Earnings per Share was 1.91 TWD — a change of -12.05% (lower).

Diluted EPS

1.68TWD

YoY

-12.05%

Last updated:

Diluted Earnings per Share of SunWay Biotech Co is 2025 1.68 TWD. Diluted Earnings per Share of SunWay Biotech Co was 2024 1.91 TWD. It decreases by -12.05% lower compared to the previous year.

The SunWay Biotech Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
-0.43 TWD
Jan 1, 2019
1.08 TWD
Jan 1, 2020
3.94 TWD
Jan 1, 2021
4.89 TWD
Jan 1, 2022
1.12 TWD
Jan 1, 2023
1.15 TWD
Jan 1, 2024
1.91 TWD
Jan 1, 2025
1.68 TWD
The SunWay Biotech Co Diluted EPS history
YEARDiluted EPSYoY
1.68TWD-12.05%
1.91TWD+65.64%
1.15TWD+3.04%
1.12TWD-77.09%
4.89TWD+24.15%
3.94TWD+265.35%
1.08TWD-351.80%
-0.43TWD-80.65%
-2.21TWD+5.67%
-2.09TWD+103.43%
-1.03TWD-7.03%
-1.11TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Diluted Earnings per Share of SunWay Biotech Co is 1.68 TWD in 2025.

Diluted Earnings per Share of SunWay Biotech Co changed from 1.91 TWD to 1.68 TWD, representing a -12.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co